Association of blood-activating commercial Chinese polyherbal preparation with clinical outcomes in older patients with ischemic cardiovascular or cerebrovascular diseases: a real-world cohort study
Su Su, Xianzhe Dong, Moyi Wang, Beibei Li, Xiaoxuan Xing, Pei Gao, Lan Zhang · 2026
Read Association of blood-activating commercial Chinese polyherbal preparation with clinical outcomes in older patients with ischemic cardiovascular or cerebrovascular diseases: a real-world cohort study by Su Su, Xianzhe Dong, Moyi Wang, Beibei Li, Xiaoxuan Xing, Pei Gao, Lan Zhang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13319001.txt.
Description
Su Su and colleagues report a 2026 real-world cohort study of a blood-activating Chinese polyherbal preparation in older patients. Participants had ischaemic heart or brain vessel disease. Data came from the Beijing medical insurance database. The team compared herbal plus antiplatelet treatment against either one alone.
In total, 12,113 patients aged 65 or older were included, with a median age of 77. Most, 78.2 percent, received the combination in this cohort. Combined treatment linked to lower odds of major cardiac and cerebrovascular events. The odds ratio was 0.687 against antiplatelet treatment alone in their analysis. Bleeding risk did not rise significantly with the combination. Several statistical approaches gave consistent results, supporting the pairing as a possible add-on strategy.
Catalog record
| CREATOR | Su Su, Xianzhe Dong, Moyi Wang, Beibei Li, Xiaoxuan Xing, Pei Gao, Lan Zhang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 29489 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |